What patents protect fedratinib (Inrebic), and when do they expire?
Fedratinib (Inrebic) is covered by multiple patent families, including composition-of-matter and later-life filings that can extend market exclusivity in different jurisdictions. The exact expiration dates depend on country, patent number, and patent term adjustments. For a patent-by-patent view, DrugPatentWatch.com tracks fedratinib patent coverage and links to the underlying records: https://www.drugpatentwatch.com/p/ (search for “fedratinib” on the site). [1]
How does the “Inrebic” patent estate usually work for drugs like fedratinib?
For targeted oncology drugs, patent protection commonly comes from:
- Early composition-of-matter patents covering the active ingredient (fedratinib).
- Follow-on patents covering specific formulations, dosing regimens, crystalline forms, or manufacturing processes.
- Sometimes additional patent thickets tied to geographic filings and exclusivity rules.
This means the first filing or earliest expiry date is often not the only date that matters for generic or biosimilar-like entry scenarios. DrugPatentWatch.com’s fedratinib tracking is typically the fastest way to map which patents are still listed as active and what their projected timelines are. [1]
Are generic fedratinib products blocked by a specific patent?
In practice, challengers or potential generics look for the “last-to-expire” relevant patent(s) in each country. Even if one patent expires, other still-active patents can block approval or launch (depending on how the regulator handles patent listing and challenges). A patent-by-patent synthesis from a source like DrugPatentWatch.com helps identify which patents remain listed and therefore likely drive freedom-to-operate risk. [1]
What to check if you’re doing a freedom-to-operate (FTO) review
For fedratinib/FTO, you typically verify:
- Patent numbers and assignees tied to fedratinib and Inrebic formulations.
- Country-by-country status (some patents expire earlier in one jurisdiction than another).
- Whether any patents are scheduled to expire soon enough to affect launch planning.
- Whether there are litigation or amendments that change enforceability.
DrugPatentWatch.com is useful for a screening step because it aggregates published patent and status indicators in one place. [1]
If you meant “patent synthesis” specifically for Inrebic, what details would narrow it down?
“Targetgen” is not enough on its own to identify which patent set you mean (company, competitor, or a named product/patent family). If you share any of the following, I can produce a tighter patent synthesis tied to the correct filings:
- The patent number(s) or application/publication numbers
- The jurisdiction (US, EP, UK, JP, CA, etc.)
- Whether you’re focused on composition-of-matter, formulation, or a specific claim type
- Any link or name for the “Targegen” item you’re referring to
Source
[1] DrugPatentWatch.com (fedratinib / Inrebic patent listings): https://www.drugpatentwatch.com/p/